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Along with several other aspects of Chagas disease, the mechanisms responsible for the different clinical
outcomes observed in chronic infected individuals have not yet been clariﬁed. It is believed that the host
immune response to the parasite plays an important role in the development of the pathology. Therefore,
the aim of this study was to evaluate the relationship between IL-10 and IFN-c gene expression proﬁle,
after in vitro stimulation of peripheral blood mononuclear cells (PBMC) with Trypanosoma cruzi recom-
binant antigens CRA (cytoplasmatic repetitive antigen) and FRA (ﬂagellar repetitive antigen), and the
clinical forms of chronic Chagas disease. Twenty patients with the cardiac form of the disease (CARD),
of whom 10 had the mild cardiac form (CARD 1) and 10 the severe cardiac form (CARD 2), and 20 patients
with the indeterminate form (IND), were selected at the Chagas Disease Unit of the Oswaldo Cruz Univer-
sity Hospital, University of Pernambuco, Recife, Pernambuco, Brazil. The PBMCs of these individuals were
cultured in the presence of CRA or FRA for 3 days and IL-10 and IFN-c gene expression was evaluated by
detection of its messenger RNA using Real Time Quantitative PCR. Although no signiﬁcant difference was
observed between the groups of individuals studied, we found that most patients with IND displayed
high levels of IFN-c gene expression, while the majority of patients with CARD 1 presented high levels
of IL-10. The results of this study thus highlight the important role that inﬂammatory cytokines play
in patients with the IND group controlling for parasite replication, and that anti-inﬂammatory cytokines
play in determining susceptibility to progression to symptomatic clinical forms of the disease.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Known as American trypanosomiasis, Chagas disease follows a
systemic and chronic course, with the ﬂagellate protozoan
Trypanosoma cruzi being the etiological agent. Considered a serious
public health problem, it is distributed throughout Latin America
and its prevalence is estimated to be 15–16 million cases, in addi-
tion to 75–90 million individuals at risk of infection [1]. The chaga-
sic cardiopathy, a major cause of congestive heart failure in Latin
America [2], and the anatomical and functional changes in
the esophagus and colon, are the main clinical manifestations of
the chronic form of the disease. Despite the serious tissue damage
observed in the cardiac (CARD) and digestive (DIG) forms of the
disease, about 50% of chronically infected individuals remain in anologia, Centro de Pesquisas
iocruz, Av. Moraes Rego s/n,
. Tel.: +55 81 2101 2674; fax:
nda Gomes).
er OA license.long period of latency, characterized by the absence of clinical
manifestations and known as indeterminate form (IND) [3,4]. The
mechanism which causes infected individuals to present different
clinical manifestations in chronic forms of the disease remains
unclear. In addition, IND patients may remain asymptomatic
throughout their lives, or may, after 10–20 years, begin to show
symptoms related to the heart or digestive system [5]. As yet, there
is no prognostic tool for predicting the clinical evolution of the
disease.
Studies of the role immunity plays in Chagas disease have doc-
umented the existence of a speciﬁc immune response to T. cruzi. It
has therefore been proposed that the absence of clinical symptoms
in IND patients is related to their ability to control the immune
response to the parasite, which does not occur in individuals with
symptomatic forms. Despite the fact that these symptomatic
patients respond effectively to the parasite, this results in exacer-
bated inﬂammation with consequent deleterious effects on tissues
[6–8].
Previous reports have observed a high frequency of activated
CD4+CD28 T cell in the peripheral blood of patients with Chagas
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with CARD and IND, respectively, suggesting different functional
roles for this cell in these individuals. [9,10]. Furthermore, acti-
vated CD8+ T cells with expression of granzyme A and TNF-a were
predominant in the inﬂammatory lesions associated with heart
disease [11]. Moreover, the levels of CD4+CD25high regulatory cells
and NKT cells (CD3+CD16CD56+) were found to be high in the
peripheral blood of IND patients, suggesting that the absence of
regulatory populations could lead to exacerbation of cytotoxic
mechanisms, culminating in tissue damage [12].
It has also been shown a clear association between IFN-c pro-
duction and the occurrence of severe heart disease, suggesting, in
the chronic phase, a relationship between this cytokine and mor-
bidity [13]. Besides this, it has been shown that T-cell clones de-
rived from the inﬂammatory inﬁltrate of CARD patients are
excellent producers of IFN-c [14].
However, different patterns of immune response have also been
found. Although IL-10 correlates with the establishment of a mod-
ulatory proﬁle in IND patients [15], this cytokine is also produced
by PBMC from CARD patients [16]. In addition, it has been shown
that there is an inverse correlation between levels of IFN-c produc-
ing CD8+ T cells and the severity of Chagas cardiomyopathy [17].
Another study in mice suggested that CD4+CD25+ T cells are inef-
fective in regulating the anti-T. cruzi immune response, since the
depletion of these cells did not alter the course of acute or chronic
infection by the parasite [18].
Therefore, the use of speciﬁc and puriﬁed T. cruzi antigens may
prove to be better for identiﬁcation of important molecules in para-
site-host interaction studies, thereby contributing to anunderstanding
of the immunopathology of Chagas disease [19]. In the present study,
the immune response in chronic Chagas disease patients was evalu-
ated after ‘‘in vitro’’ stimulation of PBMCs with two T. cruzi recombi-
nant antigens (Ags-Recs), CRA (cytoplasmatic repetitive antigen)
present in epimastigotes and amastigotes, and FRA (ﬂagellar repetitive
antigen) present in evolved forms of epimastigotes and trypomastig-
otes [20,21]. The role of these antigens in the immune response in
chronic Chagas disease patients was studied by our research group
and this has generated promising results [22–26].
This paper describes the gene expression proﬁles for IL-10 and
IFN-c in chronic Chagas disease patients, after in vitro stimulation
with CRA and FRA recombinant antigens of T. cruzi, which may im-
prove our understanding of the development of symptomatic clin-
ical forms of the disease.
2. Materials and methods
2.1. Recombinant antigens of T. cruzi
The CRA and FRA antigens were obtained as described by
Krieger [21]. The genes encoding CRA and FRA were cloned and
their expression induced using isopropyl-b-D-thiogalactoside
(IPTG). After centrifugation, proteins were puriﬁed using nickel
afﬁnity chromatography according to the manufacturer’s instruc-
tions (Qiagen, Hilden, Germany). The antigens were analyzed by
electrophoresis in polyacrylamide gel in the presence of sodium
dodecyl sulphate [27] and by silver coloration [28] to evaluate con-
tamination by Escherichia coli.
2.2. Study population
Patients diagnosed with chronic Chagas disease were selected
at the Chagas Disease Unit of Oswaldo Cruz University Hospital
(HUOC), which is associated with the University of Pernambuco
(UPE), Recife, Pernambuco, Brazil. Selection was based on the fol-
lowing criteria: (1) characterization of the clinical form using the
World Health Organization classiﬁcation [29] and an echocardio-gram; (2) two positive serum tests for Chagas disease; and (3) the
absence of previous etiological treatment. Patients underwent a
standard screening process that included medical history, physical
examination, electrocardiogram, laboratory and chest X-ray exam-
inations and echocardiography. After screening, they were grouped
as follows: the IND group (n = 20, 32–68 years old; 11women and 9
men), consisting of patients with the chronic asymptomatic form of
Chagas disease, i.e., individuals without alteration in the electrocar-
diography, chest X-ray, echocardiogram, esophagogramand barium
enema (suspicious cases); and the CARD group, consisting of pa-
tients with chronic Chagas-related cardiopathy, with or without
symptomatic cardiomyopathy and different degrees of alterations
in the echocardiogram. The CARD group was subdivided into CARD
group 1 (n = 10, 50–74 years old; 6women and 4men) including pa-
tients who exhibited no cardiac dilatation and an ejection fraction
>55% in the echocardiogram, and CARD group 2 (n = 10, 43–73 years
old; 4 women and 6 men) including patients with clinical and/or
echocardiographic and radiological signs of heart enlargement and
an ejection fraction <40% in the echocardiogram. A group of non-in-
fectedvolunteers (NI) (n = 10, 32–65 years old; 8womenand2men)
who had never received blood transfusion and presented negative
serological tests for Chagas disease was included as a control. Indi-
viduals signed an informed consent form before entering the study,
which was conducted according to the principles outlined in the
1975 Helsinki Declaration and subsequent amendments, and
approved by the local ethics committee of CPqAM/Fiocruz (No.
032009).
2.3. Serological conﬁrmation of T. cruzi infection and culture of PBMCs
Blood from patients was collected in tubes (BD Vacutainer™,
Franklin Lakes, NJ, USA) without anticoagulant to obtain serum
for conﬁrmation of T. cruzi infection and in tubes (BD Vacutainer™)
containing sodium heparin for cell culture tests. Serology was per-
formed employing two different enzyme-linked immunosorbent
assays (ELISA), one that uses a mixture of total extracts of T. cruzi
(ELISA test Chagas III Ingenieria Genetica SA Bioschile), and an-
other that uses only recombinant antigens (Immuno-ELISA Chagas
Wama Diagnostica). Positive results were recorded when both
tests were reactive, and a non-reactive response recorded when
neither test was reactive [4].
PBMCs were obtained from the tubes containing sodium hepa-
rin using density centrifugation in a Ficoll–Paque (GE Healthcare,
Uppsala, Sweden) as described previously [23]. Cell culture was
performed in 14 mL polypropylene culture tubes (Beckinton
Dickinson, San Jose, CA, USA) to a ﬁnal concentration of
5  106 cells/mL in RPMI 1640 (SIGMA–ALDRICH, St Louis, MO,
USA) supplemented with L-glutamine, 1% antibiotic (stock
of 10,000 U of penicillin, 10,000 U of streptomycin; SIGMA–
ALDRICH) and 10% of fetal bovine serum (SIGMA–ALDRICH).
Culture tubes were incubated at 37 C with 5% CO2 for 3 days,
and stimulated with either phytohemagglutinin-PHA (GIBCO,
Saranac, NY, USA) (5 lg/mL) (positive control), CRA or FRA (2 lg/
mL). Cultures without stimuli were used as a control.
2.4. Total RNA isolation, reverse transcription and real-time PCR
Total RNAwas isolated from the PBMCs using the TRIzol Reagent
(Invitrogen™, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Thereafter, total RNA was incubated with deoxyribo-
nuclease I using a Deoxyribonuclease I Ampliﬁcation Grade Kit
(Invitrogen™) to a ﬁnal RNA concentration of 100 ng/ll. Reverse
transcription (RT) into cDNA was performed using High Capacity
cDNA Reverse Transcription with RNase Inhibitor Kit (Applied Bio-
systems, Foster City, CA, USA) with random primers, according to
the supplier’s instructions.Noproductswereobserved in the control
A.S. de Melo et al. / Cytokine 58 (2012) 207–212 209(RT-) samples, inwhich the reverse transcriptasewas omitted. Real-
time RT-PCRs were carried out using 2 ll of cDNA as the starting
material in a total volume of 25 ll with TaqMan Universal PCR
Master Mix (Applied Biosystems). The thermal cycling conditions
included 2 min at 50 C and 10 min at 95 C. Thermal cycling pro-
ceeded with 40 cycles of 95 C for 0.5 min and 60 C for 2 min. All
reactions were performed in the Model ABI PRISM 7500 Sequence
Detector (PE Applied Biosystems). The sequences of primers
(400 nM) and probes (200 nM) used for ampliﬁcation of the desired
genes, have been described by Mocellin et al. [30] and follow: IL-10
sense 50-GCCGTGGAGCAGGTGAAG-30, anti-sense 50-GAAGATGT-
CAAACTC ACTCATGGCT-30, probe 6FAM-TCTTGGCTGTTACTGCCAG-
GACCCA-TAMRA; IFN-c sense 50-AGCTCTGCATCGTTTTGGGTT-3,
anti-sense 50-GTTCCATTATCCGCTACATCTGAA-30, probe 6FAM-
TCTTGGCTGTTACTGCCAGG ACCCA-TAMRA; b-actin (housekeeping
gene) sense 50GGCACCCAGCACAATGAAG-30, anti-sense 50-GCCG-
ATCCACACGGAGTACT-30, probe 6FAM-T CAAGATCATTGCTCCTCCT-
GAGAGCGC-TAMRA. The standard curves of the target and reference
genes showed similar results for efﬁciency (>90%). Thus, the relative
quantiﬁcation was calculated by the 2  DDCT method [31]. In this
method, relative quantiﬁcation was given by the ratio between the
mean CT (cycle threshold) values of the target genes and the refer-
ence gene (b-actin) in each stimulated sample in relation to a refer-
ence sample (not stimulated). Further, efﬁciency correction was
performed as described [32].
2.5. Data analysis
Statistical analysis was carried out using the D’Agostino–Pear-
son normality test followed by Student’s t-test to conﬁrm the nor-
mality of data sets. When the presumption of homogeneity was not
conﬁrmed, the Mann–Whitney test was used. To compare the aver-
age cytokine production among groups a one-way ANOVA test was
carried out, followed by Tukey’s test, and when homogeneity was
not conﬁrmed, the Kruskal–Wallis test was used, followed by the
Mann–Whitney test, whenever the averages differed. To evaluate
‘low’ and ‘high’ cytokine expression, a chi-square test was per-
formed as previously described [33]. A 5% signiﬁcance level was as-
sumed for all analyses. The software packages utilized were Excel
2000 and GraphPad Prism 5.0.3. Results
3.1. IL-10 and IFN-c gene expression after in vitro stimulation with
CRA and FRA recombinant antigens of T. cruzi
The evaluation of differences in the fold changes of gene expres-
sion for the IL-10 and IFN-c cytokines was performed by compar-
ing the mean CT values obtained after in vitro stimulation of cells
with Ags-Recs CRA and FRA of T. cruzi to values of cultures without
stimulation. For IL-10 gene expression, the distribution was homo-
geneous for all groups of patients (IND, CARD 1 and CARD 2) and
for NI individuals after stimulation with FRA and CRA. No statistical
difference in expression was observed for any of the groups evalu-
ated (Fig. 1A). Similarly, with respect to gene expression for IFN-c,
there was a homogeneous distribution around the mean value for
each group after stimulation with both Ag-Recs, with no statisti-
cally signiﬁcant difference in expression between groups of
patients and NI individuals (Fig. 1B).
3.2. Low and high fold change for IL-10 and IFN-y gene expression after
in vitro stimulation with CRA and FRA recombinant antigens of T. cruzi
In order to improve detection of fold changes in gene
expression for cytokines IL-10 and IFN-c, a cut-off was establishedcorresponding to the median of expression values for all groups
(IND, CARD 1, CARD 2 and NI). The individual values in each group
were plotted above or below the cut-off value. Although there was
no statistically signiﬁcant difference in expression between groups
of patients and NI individuals, it was observed that most CARD 1
patients presented ‘‘high’’ expression levels of IL-10 after antigen
stimulation with both Ags-Recs, with a frequency of 70% after
stimulation with CRA and 80% after stimulation with FRA. With re-
gard to gene expression for IFN-c, a ‘‘high’’ expression of this cyto-
kine was observed, mostly in IND patients, but there was no
statistically signiﬁcant difference. The frequencies obtained for this
group were 70% after stimulation with CRA and 65% after stimula-
tion with FRA (Table 1).4. Discussion
4.1. IL-10 and IFN-c gene expression after in vitro stimulation with
CRA and FRA recombinant antigens of T. cruzi
The different clinical outcomes observed in the course of
chronic Chagas disease and variations within a single clinical form
suggest that the host’s immune system, particularly the action of T
cell subsets and their cytokine production, plays a central role in
the development of pathology [6,8]. These immunological charac-
teristics could lead to the development of prognostic markers for
severe clinical forms. The use of such biological markers in identi-
fying different outcomes could help physicians to redirect
treatment [25]. In the current study, we evaluated the IL-10 and
IFN-c gene expression in patients with chronic Chagas disease after
in vitro stimulation of PMBCs with CRA and FRA T. cruzi Ags-Recs.
Our results thus revealed a homogeneous distribution in the
expression of these cytokines across all three groups of patients
(IND, CARD 1 and CARD 2) and NI individuals, with no statistical
difference in gene expression and consequently no identiﬁcation
of a possible prognostic marker.
Although an assortment of studies suggest an association
between the IND form and a high level of anti-inﬂammatory cyto-
kines, such as IL-10, and the CARD form shows high levels of pro-
inﬂammatory cytokines, such as IFN-c and TNF-a [13,15,16,34],
this study was unable to demonstrate a correlation between a par-
ticular cytokine expression proﬁle and the clinical manifestations
found in chronic Chagas disease. This corroborates the ﬁndings of
other studies [15,22,35–37]. Perhaps, differences in study popula-
tion and methodology did not allow the differential detection of
these cytokines expression in the current study.4.2. Low and high fold change in gene expression for IL-10 and IFN-y
after in vitro stimulation with CRA and FRA recombinant antigens of T.
cruzi
The categorization of patients, in relation to the production of
cytokines has been used to assess those individuals in each group
who present high levels of cytokines [15,25,33]. Gomes et al. [15],
studying the production of IFN-c, used more sensitive clinical trials
and divided the group of patients with cardiac abnormalities
according to severity of disease. It was thus possible to establish
a correlation between high and low levels of IFN-c and the pa-
tient’s clinical status. Other studies have established a cut-off point
using the median or overall mean for all study subjects, thereby
enabling them to distinguish ‘‘high’’ and ‘‘low’’ producers of cyto-
kines [25,33]. In the present study, we evaluated IL-10 and IFN-c
gene expression patterns in relation to the establishment of a
cut-off and according to severity of disease in order to identify
the high expression values and correlate it with the patient’s clin-
ical status. Despite the lack of statistically signiﬁcant differences,
Fig. 1. Detection of fold change in gene expression for the IL-10 (A) and IFN-c (B) cytokines by PBMCs of Chagas disease patients and individuals not infected after stimulation
with T. cruzi cytoplasmatic repetitive antigen (CRA) and ﬂagellar repetitive antigen (FRA). Patients with the cardiac clinical form without dilatation (CARD 1) (n = 10), cardiac
clinical form with dilatation (CARD 2) (n = 10), indeterminate clinical form (IND) (n = 20), and non-infected individuals (NI) (n = 10). The horizontal bars represent the
arithmetic mean and the standard deviation. The ANOVA test was carried out, followed by Tukey’s test or the Kruskal–Wallis test followed by the Mann–Whitney test.
Differences were taken to be statistically different when p < 0.05.
Table 1
Frequency of high cytokine producing subjects based on the overall median cytokine cut-off detected after stimulation with CRA and FRA recombinant antigens.
Cytokine/stimulus Global median cut-off High cytokine-producers (%)
IND (n = 20) CARD 1 (n = 10) CARD 2 (n = 10) NI (n = 10)
IL10-CRA 1.0 (0.1–6.2) 45 70 50 50
IL10-FRA 1.1 (0.3–6.4) 40 80 40 60
IFNc-CRA 1.6 (0.1–7.6) 70 40 40 40
IFNc-FRA 1.85 (0.1–9.8) 65 50 30 40
CRA, cytoplasmatic repetitive antigen. FRA, ﬂagellar repetitive antigen. Data are expressed as the percentage of individuals exhibiting a fold change in gene expression greater
or equal to the overall median (cut-off) calculated for each cytokine/stimulus. Patients with the cardiac clinical form without dilatation (CARD 1), the cardiac clinical form
with dilatation (CARD 2), indeterminate (IND) clinical form, and non-infected individuals (NI). The chi-square test was used and differences were taken to be statistically
signiﬁcant when p < 0.05.
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CRA and FRA, respectively, was observed for the majority of IND
patients. With regard to IL-10, it was observed that CARD 1 pa-
tients were the most proliﬁc, with frequencies of 70% and 80% after
stimulation with CRA and FRA, respectively.
The most widely accepted concept regarding the development
of chronic T. cruzi infection is that the speciﬁc immune response
to the persistence of parasites in the affected target organs results
in exacerbated inﬂammation with a consequent deleterious effect
on tissue [7]. In inﬂammation, the presence of high levels of IFN-
c appears to be explained by a lack of immunomodulatory capacity
exerted by cytokines such as IL-10.
However, an effective anti-parasite response would be critical
for controlling infection and thus preventing progression to severe
clinical forms of the disease [38]. In this regard, some studies that
assessed the CD8+ and CD4+ T cell population producing IFN-c in
individuals with chronic Chagas disease, stratiﬁed by degree ofcardiac involvement, have observed an inverse correlation be-
tween the frequency of these cells and the severity of the disease
[17,39].
In addition, there was a gradual decline in expression of surface
markers CD27+ and CD28+ with low expression of CD57+ T cells
from these CD8+ and CD4+ T cells producing IFN-c, with respect
to the severity of clinical disease. This suggests that the effector
population of T cells in chronic T. cruzi infection is characterized
by a high proportion of newly recruited T cells. Thus, over time
the population of parasite-speciﬁc memory T cells producing IFN-
c begins to show signs of senescence and loss of differentiated
cells, leading to progression to more severe cardiac involvement
[40].
These studies therefore support the idea that chronic persis-
tence of the parasite in tissues would lead to a continuous anti-
genic stimulation, resulting in the exhaustion of the T cell
population. Individuals begin to exhibit low frequencies of CD8+
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predispose them to progression of the disease, i.e., the permanence
of the parasite in tissues could lead to a failure of the host’s im-
mune response to control parasite replication, thereby bringing
on severe symptoms of the disease. Moreover, the intensity of par-
asite infestation, which is inﬂuenced by genetic factors in the par-
asite and in host’s immune response may determine the level of
exhaustion of the immune system and even the extent to which
the disease progresses [17,39,40].
Conversely, even considering the regulatory role of IL-10, as
IND patients had a higher frequency of IL-10+ cells in the subpop-
ulation of regulatory T cells CD4+CD25highFoxP3+ [12], a recent
study in mice suggests that CD4+CD25+ cells do not have an effec-
tive role in regulation of the anti-T. cruzi immune response, since
depletion of these did not alter the course of acute or chronic
infection by the parasite [18]. Moreover, the presence of
cytokines with immunoregulatory properties, such as IL-10 and
TGF-b, in the course of T. cruzi infection was found to be related
to increased susceptibility to infection, possibly inhibiting IFN-c
trypanocidal activity [41,42].
Vitelli-Avelar et al. [33], when assessed the cytokine patterns of
circulating leukocytes from chagasic patients without stimulus,
demonstrated that most IND individuals presented a dominant
regulatory cytokine proﬁle, whereas CARD individuals displayed
a dominant inﬂammatory cytokine pattern. Although, after stimu-
lation in vitro with T. cruzi trypomastigotes, the cytokine proﬁle
was the opposite, i.e., CARD patients began to show higher cyto-
kine production of regulatory status, whereas IND patients began
to exhibit a cytokine predominantly inﬂammatory proﬁle. A simi-
lar inversion could be found by them after in vivo treatment of
IND and CARD individuals with benzonidazole. Thus, the antigenic
stimulation may mimicry what is occurring in tissues microenvi-
ronment, where are taking place the antigen exposure.
Previous results obtained by our group regarding the immune
response of cells from Chagas patients using CRA and FRA T. cruzi
antigens found substantial production of IFN-c and TNF-a by Cha-
gas patients in comparison with NI, after stimulation with the CRA,
but not among the clinical forms [23]. Lorena et al. in 2010 [25],
carried out an evaluation of cytokine production using ﬂow cytom-
etry and observed that CARD 2 patients presented high levels of
IFN-c and TNF-a produced by CD8+ T cells compared to CARD 1 pa-
tients after stimulation with CRA, indicating an association be-
tween severity of heart damage and high levels of inﬂammatory
cytokines.
In the study above mentioned, were highlighted the importance
of analysis of cytokine production by speciﬁc cell populations for
improving understanding of the role of a speciﬁc cell subtype in
the development and maintenance of the immune response to
the parasite. Nevertheless, the development of the disease may
not be related solely to the effector function of isolated cell groups,
but also to the set of all responses that occur. Thereby, overall anal-
ysis of cytokine production is also an important approach to under-
standing the immune response in these patients.
Therefore, as in the current study, approaches that analysis
cytokines and others immunological factors by gene expression
could provide a broad view of what is occurring. There are a few
studies conducted using qPCR and microarray approaches in
mouse models of T. cruzi infection as well as in hearts of chronically
chagasic patients. In these studies were found correlations be-
tween some cytokine expression and disease outcomes [43,44],
no correlation [45] and as in our study some inversely correlations
[46,47]. Thus, the differences between our results and those of pre-
vious investigators could be attributed to the different samples
used, to the use of mammalian cell lines, human cells or whole-ani-
mal models, different parasite strains used or stimulus, or other
differences in experimental design.Therefore, since the present study found a higher frequency of
gene expression for IFN-c in IND patients, along with a higher fre-
quency of gene expression for IL-10 in CARD 1 patients, although
these differences were not statistically signiﬁcant, we must draw
attention to the important role cytokines such as IFN-c play in
IND patients in producing an effective immune response to the
parasite and preventing its multiplication, thereby avoiding tissue
damage and allowing these patients to remain without clinical
symptoms. On the other hand, CARD 1 patients may be experienc-
ing a deﬁciency in this effective immune response, both because of
the exhaustion of the immune system and the production of
immunosuppressive cytokines such as IL-10, since this is one of
the release mechanisms used by the parasites, effecting a low spe-
ciﬁc immune responses and facilitating their permanence and mul-
tiplication, which may lead to heart tissue damage in these
patients.
Finally, understand the delicate balance of multiple factors in-
volved in the pathogenesis of Chagas disease is a complex task,
the mechanisms involved in the interaction of immune cells and
the differential genetic susceptibility of the host, may give rise to
a highly complex disease, making it difﬁcult to detect a speciﬁc im-
mune response.5. Conclusion
In conclusion, evaluation of IL-10 and IFN-c gene expression in
chronic Chagas disease was unable to ﬁnd any differences between
the IND, CARD 1 and CARD 2 groups of individuals. It was therefore
not possible to identify a prognostic marker that could aid treat-
ment and improve management of these patients. Moreover,
although this was not statistically different, we observed a higher
frequency of IFN-c gene expression in IND patients and a higher
frequency of IL-10 gene expression in CARD 1 patients, after
in vitro stimulation with recombinant T. cruzi antigens. We there-
fore believe that the role of cytokines in determining Chagas dis-
ease outcomes requires further investigation that takes into
account other variable factors, such as the genetic history of the
parasite and the host.Conﬂict of interest
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